Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of diflunisal in transthyretin hereditary amyloidosis
2010-019829-34Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diflunisal in hereditary transthyretin amyloidosis (hATTR) and hereditary sensory neuropathy (HSAN), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Evaluation of neuropathy. Started Apr 2010; status: completed.
02
Drugs
diflunisal
03
Conditions
hereditary transthyretin amyloidosis (hATTR)hereditary sensory neuropathy (HSAN)
Beyond the preview
Go deeper on 2010-019829-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019829-34.